Neuraminidase inhibitors tied to lower death risk with H1N1

03/21/2014 | Healio (free registration) · Medscape (free registration)

An analysis of 78 studies involving more than 29,000 adults hospitalized for H1N1 influenza found that treatment with neuraminidase inhibitors was associated with a 19% lower mortality risk, regardless of the timing, compared with no treatment. Patients who received neuraminidase inhibitors within two days of illness onset were about half as likely to die as those treated later. The findings appear in The Lancet Respiratory Medicine.

View Full Article in:

Healio (free registration) · Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ